PRIMARY STUDY
Recent Updates in Psychopharmacology for the Core and Associated Symptoms of Autism Spectrum Disorder
Key Findings: Early studies on the use of cannabidiol (CBD) to reduce irritability in patients with autism spectrum disorder (ASD) have failed to show safety or efficacy. More research is needed.
Type of Study: Meta-analysis
Study Result: Inconclusive
Research Location(s): United States
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
Ligands Studied: Oxytocin, Serotonin, Vasopressin
Citation: Thom RP, et al. Recent Updates in Psychopharmacology for the Core and Associated Symptoms of Autism Spectrum Disorder. Curr Psychiatry Rep. 2021; 23:79. doi: 10.1007/s11920-021-01292-2
Authors: Thom RP, Pereira JA, Sipsock D, McDougle CJ
